含2-苯氧乙醇多剂量瓶装13价肺炎球菌结合疫苗(PCV13)在健康婴儿中按常规接种的免疫原性与安全性:一项开放标签随机对照试验
在冈比亚婴儿中开展的开放标签随机对照试验,将含防腐剂2-苯氧乙醇的多剂量瓶装PCV13与不含2-苯氧乙醇的单剂量预充式注射器PCV13进行比较。500名婴儿按1:1随机分配,在2、3、4月龄接种,5月龄时评估免疫应答。结果显示多剂量瓶装PCV13对所有13种血清型均非劣效于单剂量预充式注射器,安全性和耐受性相当。
要点
- 多剂量瓶装PCV13对所有13种血清型均达到免疫原性非劣效于单剂量预充式注射器。
- 两组安全性和耐受性相当。
- 多剂量瓶装PCV13可能有助于优化资源有限地区的疫苗接种。
核心结论
- 按常规接种程序给予婴儿多剂量瓶装PCV13是安全和具有免疫原性的。
- 多剂量瓶装PCV13对所有13种肺炎球菌血清型均非劣效于单剂量预充式注射器。
- 多剂量瓶装PCV13与单剂量预充式注射器的免疫原性和安全性特征相当,提示多剂量瓶装PCV13可帮助优化资源有限地区的疫苗接种。
研究设计与样本
- 开放标签随机对照试验,在冈比亚婴儿中开展。
- 500名参与者被随机分配并接种疫苗,489名完成试验(多剂量瓶装组n=245;单剂量预充式注射器组n=244)。
- 婴儿按1:1随机分配,在2、3、4月龄分别接受多剂量瓶装或单剂量预充式注射器PCV13。
- 在5月龄时测量血清型特异性抗肺炎球菌抗体应答和调理吞噬活性(OPA;子集)。
主要发现
- 多剂量瓶装PCV13在所有血清型上均达到非劣效性,以达到IgG浓度≥0.35μg/mL的受试者比例衡量(主要终点)。
- IgG几何平均浓度(GMC;共同主要终点)也显示多剂量瓶装PCV13非劣效;OPA结果支持这些发现。
- 两组安全性和耐受性相当。
关键数值与推荐
- 非劣效性判定标准:达到IgG浓度≥0.35μg/mL的受试者比例差值(多剂量瓶装-单剂量预充式注射器)的97.5%CI下限大于-10%。
- IgG GMC非劣效性判定标准:几何均值比(多剂量瓶装 vs 单剂量预充式注射器)的双侧97.5%CI下限大于0.5。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This open-label randomized controlled trial in infants compared safety, tolerability, and immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13) formulated with the preservative 2-phenoxyethanol (2-PE) in a multidose vial (MDV) to the current PCV13 without 2-PE in a single-dose syringe (SDS). METHODS: Gambian infants were randomized 1:1 to receive PCV13 as either MDV or SDS at ages 2, 3, and 4months. Serotype-specific antipneumococcal antibody responses and opsonophagocytic activity ([OPA]; subset) were measured at age 5months. Noninferiority was declared if the lower bound of the 97.5% CI for the difference (MDV-SDS) in proportions of subjects achieving IgG concentrations ≥0.35μg/mL (primary endpoint) was greater than -10%. IgG geometric mean concentrations (GMCs) were noninferior if the lower limit of the two-sided 97.5% CI of the geometric mean ratio (MDV vs SDS) was greater than 0.5. Reactogenicity and other adverse events were collected. RESULTS: 500 participants were randomized and vaccinated; 489 (MDV: n=245; SDS: n=244) completed the trial. Noninferiority of MDV was demonstrated for all serotypes as measured by percentage of subjects achieving antibody responses above ≥0.35μg/mL. IgG GMCs (coprimary endpoint) also demonstrated noninferiority of MDV; OPA results supported these findings. Safety and tolerability were comparable between groups. CONCLUSIONS: PCV13 in MDV was safe and immunogenic when administered according to the routine schedule to infants. MDV was noninferior to SDS for all 13 pneumococcal serotypes. Comparable immunogenicity and safety profiles of PCV13 MDV and SDS suggest PCV13 MDV can help optimize vaccination in resource-limited settings. ClinicalTrials.gov NCT01964716 https://clinicaltrials.gov/ct2/show/NCT01964716.
引用
- Idoko OT, Mboizi RB, Okoye M, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) formulated with 2-phenoxyethanol in multidose vials given with routine vaccination in healthy infants: An open-label randomized controlled trial. Vaccine. 2017. PMID: 28479175. doi:10.1016/j.vaccine.2017.04.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。